NASDAQ:ABVX Abivax Q2 2025 Earnings Report $93.77 +3.16 (+3.49%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$93.42 -0.34 (-0.37%) As of 10/10/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Abivax EPS ResultsActual EPS-$0.86Consensus EPS -$0.90Beat/MissBeat by +$0.04One Year Ago EPSN/AAbivax Revenue ResultsActual RevenueN/AExpected Revenue$1.35 millionBeat/MissN/AYoY Revenue GrowthN/AAbivax Announcement DetailsQuarterQ2 2025Date9/8/2025TimeAfter Market ClosesConference Call DateMonday, September 8, 2025Conference Call Time11:45AM ETConference Call ResourcesPress ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseInterim Report Abivax Earnings HeadlinesFY2027 EPS Estimates for Abivax Lifted by Leerink Partnrs2 hours ago | americanbankingnews.comAbivax price target raised, named a ‘Best Idea’ at GuggenheimOctober 10 at 2:48 PM | msn.com2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day. | Crypto Swap Profits (Ad)A Look at Abivax (ENXTPA:ABVX) Valuation Following Phase 3 Success for Obefazimod in Ulcerative ColitisOctober 10 at 9:45 AM | finance.yahoo.comAnalysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) PT at $102.14October 9 at 2:16 AM | americanbankingnews.comBTIG Maintains ABIVAX Société Anonyme - Depositary Receipt (ABVX) Buy RecommendationOctober 8 at 3:22 AM | msn.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxFounded in 2013 and headquartered in Paris, France, Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide.View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
